PURPOSE: A pharmaceutical composition for treating liver cancer and a liver cancer treating method using adenine nucleotide translocator 2 expression or activity inhibitor is provided to reduce ANT2 gene expression of hepatoma cells.CONSTITUTION: A pharmaceutical composition for treating liver cancer contains adenine nucleotide translocator 2 small interfering RNA(ANT2 siRNA) or ANT2 short hairpin RNA(shRNA) as an active ingredient. The ANT2 siRNA or the ANT2 shRNA induces decomposition of ANT2 mRNA by combining the anti-sense sequence described in the sequence number 3(SEQ ID NO:3) unites with the sense sequence described in the sequence number 1. The composition multiplies the expression of the tumor suppressor gene SOCS 1(suppressor of cytokine signaling 1). The composition drops the DNA methyltransferase activity. The composition reduces the hypermethylation of the CpG islands of SOCS 1(suppressor of cytokine signaling 1) promoter. The composition reduces the activity of STAT 3(signal transducer and activator of transcription). The composition reduces the expression of the microRNA- 21 (miR-21).COPYRIGHT KIPO 2013본 발명은 adenine nucleotide translocator 2(ANT2) 발현 또는 활성 억제제를 이용하여 간암을 치료하는 방법에 관한 것이다. 구체적으로, 본 발명은 Adenine nucleotide translocator 2 small interfering RNA (ANT2 siRNA) 또는 ANT2 short hairpin RNA (shRNA) 를 유효성분으로 함유하는 간암 치료용 약학적 조성물을 제공한다. 또한, 본 발명은 ANT2 siRNA 또는 ANT2 shRNA를 환자에게 투여하여 간암을 치료하는 방법을 제공한다.궁극적으로, 본 발명은 간암 세포 성장 억제 효과 및 우수한 치료 효능을 가지는 간암 치료제를 제공할 수 있을 것이며, 간암 치료제 개발에 이용될 수 있을 것으로 기대된다.
